Document Detail

Custom oligonucleotide array-based CGH: a reliable diagnostic tool for detection of exonic copy-number changes in multiple targeted genes.
Jump to Full Text
MedLine Citation:
PMID:  23340513     Owner:  NLM     Status:  Publisher    
The frequency of disease-related large rearrangements (referred to as copy-number mutations, CNMs) varies among genes, and search for these mutations has an important place in diagnostic strategies. In recent years, CGH method using custom-designed high-density oligonucleotide-based arrays allowed the development of a powerful tool for detection of alterations at the level of exons and made it possible to provide flexibility through the possibility of modeling chips. The aim of our study was to test custom-designed oligonucleotide CGH array in a diagnostic laboratory setting that analyses several genes involved in various genetic diseases, and to compare it with conventional strategies. To this end, we designed a 12-plex CGH array (135k; 135 000 probes/subarray) (Roche Nimblegen) with exonic and intronic oligonucleotide probes covering 26 genes routinely analyzed in the laboratory. We tested control samples with known CNMs and patients for whom genetic causes underlying their disorders were unknown. The contribution of this technique is undeniable. Indeed, it appeared reproducible, reliable and sensitive enough to detect heterozygous single-exon deletions or duplications, complex rearrangements and somatic mosaicism. In addition, it improves reliability of CNM detection and allows determination of boundaries precisely enough to direct targeted sequencing of breakpoints. All of these points, associated with the possibility of a simultaneous analysis of several genes and scalability 'homemade' make it a valuable tool as a new diagnostic approach of CNMs.European Journal of Human Genetics advance online publication, 23 January 2013; doi:10.1038/ejhg.2012.279.
Aurélie Vasson; Céline Leroux; Lucie Orhant; Mathieu Boimard; Aurélie Toussaint; Chrystel Leroy; Virginie Commere; Tiffany Ghiotti; Nathalie Deburgrave; Yoann Saillour; Isabelle Atlan; Corinne Fouveaut; Cherif Beldjord; Sophie Valleix; France Leturcq; Catherine Dodé; Thierry Bienvenu; Jamel Chelly; Mireille Cossée
Related Documents :
24517913 - The "cold-pcr approach" for early and cost-effective detection of tyrosine kinase inhib...
12489043 - A mutation in the fibroblast growth factor 14 gene is associated with autosomal dominan...
24379153 - Genetic factors that increase male facial masculinity decrease facial attractiveness of...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-23
Journal Detail:
Title:  European journal of human genetics : EJHG     Volume:  -     ISSN:  1476-5438     ISO Abbreviation:  Eur. J. Hum. Genet.     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-1-23     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9302235     Medline TA:  Eur J Hum Genet     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Assistance Publique-Hôpitaux de Paris, Laboratoire de Biochimie et Génétique Moléculaire, Hôpital Cochin, APHP, Paris, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): Eur J Hum Genet
Journal ID (iso-abbrev): Eur. J. Hum. Genet
ISSN: 1018-4813
ISSN: 1476-5438
Publisher: Nature Publishing Group
Article Information
Download PDF
Copyright © 2013 Macmillan Publishers Limited
Received Day: 06 Month: 08 Year: 2012
Revision Received Day: 31 Month: 10 Year: 2012
Accepted Day: 13 Month: 11 Year: 2012
Print publication date: Month: 09 Year: 2013
Electronic publication date: Day: 23 Month: 01 Year: 2013
pmc-release publication date: Day: 1 Month: 9 Year: 2013
Volume: 21 Issue: 9
First Page: 977 Last Page: 987
PubMed Id: 23340513
ID: 3746255
Publisher Item Identifier: ejhg2012279
DOI: 10.1038/ejhg.2012.279

Custom oligonucleotide array-based CGH: a reliable diagnostic tool for detection of exonic copy-number changes in multiple targeted genes Alternate Title:CGH array for diagnosis of heterogeneous diseases
Aurélie Vasson1
Céline Leroux1
Lucie Orhant1
Mathieu Boimard1
Aurélie Toussaint1
Chrystel Leroy1
Virginie Commere1
Tiffany Ghiotti1
Nathalie Deburgrave1
Yoann Saillour2
Isabelle Atlan1
Corinne Fouveaut1
Cherif Beldjord12
Sophie Valleix12
France Leturcq12
Catherine Dodé12
Thierry Bienvenu12
Jamel Chelly12
Mireille Cossée12*
1Assistance Publique-Hôpitaux de Paris, Laboratoire de Biochimie et Génétique Moléculaire, Hôpital Cochin, APHP, Paris, France
2Institut Cochin, Département de Génétique et Développement, Université Paris Descartes, INSERM U1016, CNRS UMR 8104, Paris, France
*Laboratoire de Génétique Moléculaire CHU Montpellier/INSERM U827 IURC, Institut Universitaire de Recherche Clinique 641, Avenue du Doyen Gaston Giraud, MONTPELLIER, Cedex 5, 34093, France. Tel: +33 (0)4 11 75 98 79 ou 98 63; Fax: +33 (0)4 11 75 98 82; E-mail:


Large intragenic deletions and duplications are frequent causes of genetic disorders. The term of copy-number mutations (CNMs) is used, from the standpoint pathological relevance, in distinction to the neutral term ‘copy-number variation' CNV, in accordance with previous studies.1 Thus, in the diagnostic context, search for CNMs represents a major purpose, particularly if they are frequent such as for Duchenne or Becker dystrophies (DMD/BMD) in which they represent 60–70% of mutations.2, 3 However, in diseases for which CNMs are rare, their search is important for diagnostic confirmation if screening for point mutation is negative or incompletely conclusive. For example, in cystic fibrosis (CF) CNMs represent 1.5% of known CFTR mutations and are searched for in patients heterozygous for point mutations in CFTR.4

Several scanning methods for CNMs, including Southern blotting, multiplex amplifiable probe hybridization (MAPH), quantitative multiplex PCR of short fluorescent fragments (QMPSF), multiplex ligation-dependent probe amplification (MLPA) are currently used5, 6, 7 but they have several disadvantages. The preparation of high-quality Southern blot is technically demanding, is time consuming and its sensitivity is generally low and limited to very large CNMs.8 It has been shown that QMPSF approach used in several studies was inherently biased in favor of the detection of deletions over duplications, suggesting that a change of copy-number from two to one (in the case of heterozygous deletions) is more readily identifiable than change from two to three (in the case of heterozygous duplications).4, 9 MLPA approach seems more reliable as it is based on hybridization of probes to genomic regions of interest. However, this technique is available in commercial kit forms in which the number of probes is usually limited to one per exon. For diseases with rare CNMs, commercials kits such as MLPA are not available and scanning methods are represented by ‘home made' techniques such as semi-quantitative-fluorescent-PCR (QF-PCR) and real-time quantitative-PCR (Q-PCR) that are time consuming for implementation. As PCR-based techniques and MLPA are restricted to a limited number of targeted sequences, they can fail to detect some rearrangements; conversely false-positive single-exons losses can result from single nucleotide polymorphisms (SNPs) affecting primer or probe sequences.10 Finally, these scanning methods do not allow determination of CNM boundaries, and a limited number of genes can be concomitantly analyzed. In general, each gene requires its specific kit or ‘home-made' technique for CNM detection.

The recent emergence of array comparative genomic hybridization has revolutionized the ability to identify CNMs associated with various diseases. This approach was first used for detecting large CNMs at the scale of multiple contiguous genes in whole genome analysis.11 In recent years, the development of oligonucleotide probes for hybridization on microarrays allowed to explore smaller CNMs at the scale of exons. Single-locus arrays were first validated to detect exonic and intronic CNMs within the DMD locus and the CFTR locus in patients suspected of having mutations in these genes.1, 8, 10, 12 Thereafter, several teams (including our) implemented multiple gene CGH arrays.13, 14, 15 Custom oligonucleotide CGH array emerged then as a powerful tool for high-resolution detection of genomic CNMs, with the flexibility provided through customized array designs. The recent possibility of increasing the density of probes loaded on chips allowed the emergence of high-density (HD) chips arrays thereby increasing the number of genes tested.16

In our laboratory of Molecular Biology, Cochin Hospital (Paris), we are performing molecular diagnosis of several genetic diseases with various clinical aspects, mutational spectrum and modes of inheritance. Some of them are known to be caused, in different proportions, to CNMs (Table 1).1, 2, 3, 4, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33 Conventional methods used to search for CNMs are mainly based on QF-PCR and MLPA. In order to replace the time-consuming current scanning methods by a unique technique for CNMs detection, we first developed a 72k four-plex array covering the 158 exons of eight disease-related genes: DMD, sarcoglycan genes and CFTR.13 Exonic copy-number changes were identified with a high resolution, as abnormalities of about 1.5–2 kb could be detected, as well as a mosaic deletion.13 We then wanted to implement this approach to the totality of genes tested in our laboratory that are known or suspected to be prone to CNMs (26 genes). We took advantage of the advent of HD chips to develop a custom-targeted 12-plex 135K oligonucleotide-based CGH array covering the 344 exons of these genes. We report implementation and validation of this array and its applications in a diagnostic setting to test different diseases with great clinical and genetic heterogeneity.

Patients and methods
Patients and control samples

The patients were referred to the Laboratory of Molecular Biology, Cochin Hospital, for molecular analysis of the genes of interest. Reference DNAs were obtained from control patients with a well characterized deletion of exons 7 and 8 of the CFTR gene.13 Genomic DNAs were extracted from leukocytes using standard procedures (phenol extraction or Wizard Genomic DNA Isolation System, Promega, Madison, WI, USA).

CGH array
Microarray construction

We devised, with Roche Nimblegen support, 12-plex oligonucleotide-based CGH arrays to explore the whole 26 genes including promoters. The design was made by taking in consideration size and constitution of each gene (Table 2). Using the data from the human genome (, NCBI36/hg18), 135 000 oligonucleotide probes covering all genomic regions plus 2 kb at each extremity of the 26 genes were designed for each subarray. On the basis of experimental results, different average tiling intervals (ie, spacing between 5′ ends of probes) were selected (Table 2). ‘Backbone' probes covering chromosomes corresponding to the genes of interest were added at a lower density (spacing of 20–25 kb) in intergenic regions. All probes have similar characteristics: isothermal probes with melting temperature (Tm) of 76 °C and average probe length 60 bases. To avoid cross-hybridization, all probes were compared with the entire hg18 genome using Basic Local Alignment and Search Toll. Any probe that did not map uniquely was removed except those in the pseudoautosomal regions on chromosome X and Y for which two locations were tolerated. Roche NimbleGen manufactured the array ( Sequences of the 135 000 probes are available on request.

Fluorescent DNA labeling, microarray hybridization

DNA concentration and quality were evaluated by NanoDrop and agarose gel migration. The reference DNA used for each patient's DNA was extracted using the same technique. We did sex match between each sample and reference DNA. Each DNA sample (1 μg) was labeled using a NimbleGen Dual-Color DNA labeling Kit as described previously13 according to the manufacturer's protocol (Roche NimbleGen). After denaturation, hybridization was carried out on a NimbleGen Hybridization System for 40 h at 42 °C. The array was then washed by using NimbleGen Wash System (Roche NimbleGen), dried by centrifugation and scanned at 2 μm resolution by using InnoScann900 scanner (Innopsys, Toulouse, France).

Data analysis

Fluorescence intensity raw data were obtained from scanned images of the oligonucleotide arrays by using NimbleScan 2.6 extraction software (Roche NimbleGen). For each spot on the array, log2 ratio of the Cy3-labeled test sample versus Cy-5 reference sample was calculated and visualization of the results was obtained using the Signal map software (Roche NimbleGen). Quality of the experiment was ascertained by the mad1.dr value (medium absolute deviation of the log2 ratio difference between consecutive probes) that provides a surrogate measure of experimental noise and should be <0.23.

DNA sequencing

CGH array results were used to target the genomic region to design primers for sequencing breakpoints. Primers were first selected within a 500-bp interval and further in a 1-kb interval if necessary. Oligonucleotide primer pairs were designed with the help of the Primer3Plus online tool ( Sequences of primers are available on request. Bidirectional sequencing of the purified PCR products was performed on an Applied (3130XT) automated capillary sequencer (Applied Biosystems, Foster City, CA, USA) (protocols available on request).

Development of a custom 12-plex CGH array for CNM detection in 26 genes

In order to define the CGH array design that allows analysis of the greatest number of genes despite the constraint related to the possible number of probes, we performed preliminary experiments and compared four different designs; design 1: exons and introns were homogeneously covered by evenly distributed probes, with tiling space of 24 bp; design 2: only exons were covered by probes, and each exon was covered by 30–40 probes; design 3: exons and flanking intronic sequences were covered by 30–40 probes, and introns were covered by probes with spacing of 600 bp; design 4: exons and flanking intronic sequences were covered by 30–40 probes, and introns were covered by probes with a spacing of 100 bp. These experiments showed that design 2 was not suitable because of deviations from the expected baseline of log2 ratio corresponding to several consecutive probes. Design 3 and design 4 that require a much less number of probes than design 1 were appropriate to efficiently detect exonic CNMs. It appeared through these experiments that inclusion of a set of backbone probes covering intergenic regions would also contribute to overcome baseline irregularity.

We selected 26 genes routinely analyzed in our laboratory involved in heterogeneous groups of disorders and prone or suspected to be prone to CNMs (Tables 1 and 2). Genomic size and organization are highly variable between these genes, from the small tubulin genes with their four exons spanning about 4 kb of genomic DNA to the DMD gene spanning on 2.2 Mb and composed of 79 exons (Table 2). We developed a custom-targeted oligonucleotide-based CGH array containing 135 000 oligonucleotide probes covering genomic regions of these 26 genes, including their promoters and 2-kb upstream and downstream regions. A total of 344 exons, 26 promoters and corresponding intronic regions were then covered (Table 2). For each gene, the design of the 60mer probes was determined according to the characteristics of the gene and the preliminary experiments, in order to optimize visualization on CNMs (Table 2). For the 12 smaller genes (4–9 kb), exons and introns were covered by a HD of probes (tiling of 15 bp). For large genes, we chose to cover introns with a lower probe density (one probe each 300 bp) than exons (one probe each 40 bp) to save space on the array, except for the CFTR and DMD genes. For these two genes, intronic coverage was as dense as exonic coverage (tiling of 20 bp for CFTR and 50 bp for DMD) to improve determination of breakpoints. Backbone probes were added at a lower density in intergenic sequences to obtain a stable baseline.

Validation of the custom CGH array by analysis of control DNAs

The performance of the custom CGH array was evaluated by using 38 DNA samples from patients with known CNMs previously identified by other techniques (Table 3). They ranged from small CNMs of one unique exon to entire gene rearrangements. Control patients were hemizygous, homozygous or heterozygous, and three somatic mosaicism were included.

Through the use of strict quality criteria, particularly the mad1.dr value below 0.23, no false-negative result was observed. All the 38 CNMs were accurately identified and precisely characterized, although rearrangements are of different size and scattered in different genomic regions (Table 3). The smallest deletion was a heterozygous 1.5 kb deletion of exons 22 and 23 within the CFTR gene that span 189 kb of genomic DNA (patient 26). We tested several monoexonic CNMs in the DMD gene, including a heterozygous duplication. All were correctly identified, as well as the frequent small CNV (1.4 kb) in intron 2 of this gene (Figure 1a). We also analyzed one DNA sample from chorionic villosities with a deletion in the DMD gene, which was correctly detected. A heterozygous deletion of exon 1 of the CDKL5 gene (patient 27), which was difficult to detect by using MLPA because it appeared as a dosage reduction of a single peak among 45 signals, was easily visualized using CGH array, as it extends in fact on a large distal genomic region of 294 kb (Figure 2).

To assess the threshold of CNM detection with this procedure, we analyzed DNAs from three controls with somatic mosaicism. We reanalyzed DNA from a BMD patient with mosaicism in the DMD gene previously tested with the 4-plex design (patient 10, exons 49–52 deletion, 80:20 mutant:wild-type (WT)),13 this mosaic deletion was correctly detected (data not shown). We also analyzed a male patient with lissencephaly who had a somatic mosaicism for a deletion in the DCX gene (patient 28; 40:60, mutant:WT). The deletion was detected with a log2 ratio of −0.4 (data not shown). To refine our evaluation, we then tested DNA from a female carrier with a heterozygous duplication within the DMD gene in approximately 50% of cells (sample 16). CGH array analysis identified clearly the mosaicism as a gain of signal with a log2 ratio of +0.3, instead of the 0.4 expected value for a heterozygous female (Figure 3).

Finally, relevance of inclusion of backbone probes was evaluated through analysis of deletions encompassing entire genes and extending outside of the gene regions. We tested four DNA samples from patients with lissencephaly because of heterozygous deletions of the whole LIS1 gene (patients 31–34). The deletions were clearly identified, and boundaries roughly determined because of the low density of backbone probes in intergenic regions. The larger deletion was identified in a patient with Miller–Dieker syndrome, a contiguous gene disorder because of chromosome 17p13.3 deletion including LIS1 (Figure 4a). We also analyzed two samples from patients with Kallmann syndrome because of large deletions of the entire KAL1 gene (patients 35 and 36), including one with associated ocular albinism (patient 35). CGH array detected a large deletion of 2297 kb encompassing not only the whole KAL1 gene but also neighboring genomic region including GPR143 (Figure 4b), which is known to be associated, when mutated, with ocular albinism phenotypes.34

Use of the custom CGH array for diagnosis and genetic counseling

Following validation by using control DNAs with various gene CNMs, we decided to apply it as a diagnostic tool for patients with unknown molecular diagnosis and/or waiting for genetic counseling. CNM screening strategy varied according to genetic characteristics of the pathology (Table 1).

We applied the custom CGH array as a first diagnostic method to investigate the DMD gene in 262 DNA samples from patients (or relative women if DNA from patient is not available) for whom clinical, biological and histological data were compatible with the diagnosis of dystrophinopathy. We identified 102 deletions (90 hemizygous and 12 heterozygous), 40 duplications (31 hemizygous and 9 heterozygous) and 2 complex rearrangements in the DMD gene. Single-exon CNMs were easily detected as they encompass in general part of flanking intronic regions. In contrast, rearrangements involving entire genes were visualized as a shift of the baseline corresponding to backbone probes in the intergenic regions. Interestingly, in a case of isolated duplication of exon 44 detected by cDNA analysis but not by QF-PCR, CGH array identified the duplication and showed that the proximal breakpoint was very close to exon 44. The primer used for QF-PCR was outside of the duplicated region, accounting for the false-negative result (data not shown). We detected, in two DMD families, a complex rearrangement, that is, CNMs involving different genomic parts of the gene and/or with more than two breakpoint junctions. The first case was the association of a duplication of exons 61–62, a duplication of exons 65–67 and abnormal values of log2 ratio for exons 68–79 probes suggesting a triplication. Exons 63–64 were normal. We confirmed by real-time Q-PCR that exon 63 was normal, exon 67 duplicated and exon 68 triplicated (Figure 5A). CGH array analyses performed in samples from three relative women of different generations showed that the rearrangement were stable and transmitted ad integrum. The other case of complex rearrangement in the DMD gene was identified in a heterozygous female and associated a duplication of exons 8–41, a duplication of exons 44–51 and a triplication of exons 42–43, confirmed by real-time Q-PCR (data not shown). Breakpoints characterized by CGH array were used to choose oligonucleotides for sequencing 20 patients with various deletions in the DMD gene (article in preparation). The real breakpoints were distant in average of 190 bp for the proximal breakpoint (SD=242 bp) and 267 bp for the distal breakpoint (SD=275 bp). In most cases (n=33 sequences), the difference was <500 bp and sequencing was successful using the first set of primers chosen on the basis of CGH array boundaries (see Patients and methods section).

We also used the custom CGH array as a second-line diagnostic method to test DNA samples from 83 patients (or relatives when not available) with phenotypical data very suggestive of a disease and for whom only one point mutation or no point mutation was detected (18 Rett – typical or atypical – syndrome or neonatal encephalopathy, 42 CF or CFTR-related disorder, 23 severe hemophilia A). We identified 16 CNMs involving either MECP2 (n=8), CDKL5 (n=2), CFTR (n=3) and the F8 gene (n=3). CNMs involving MECP2 were two heterozygous deletions in Rett females, five hemizygous large duplications including the entire MECP2 gene and a large complex duplication–triplication (Figure 5B) in males with neonatal encephalopathy. Two heterozygous large deletions of CDKL5 and neighboring genomic regions were identified in females with atypical Rett syndrome. In CF patients, we identified three heterozygous CNMs involving CFTR, including the smallest CNM identified in this study (deletion of exons 25 and 26, 1.4 kb) (Figure 1b). CNMs were identified in the F8 gene in three families with severe hemophilia A, two heterozygous CNMs (one deletion of two exons, one duplication of eight exons) in carrier females (affected males deceased) and a hemizygous deletion of five exons in a male patient.

We also used CGH array for genetic counseling in the family of patient 36 affected by Kallmann syndrome. Analysis of his unaffected mother revealed that the large deletion (whole KAL1 gene and neighboring genomic region) is not present in leukocytes from the mother (Figure 4b).


CNM detection has improved considerably over the past 15 years. Initially, large rearrangements were characterized by Southern blot technology, which is a manual and time-consuming method. Appeared then fluorescent semi-quantitative PCR techniques and real-time quantitative PCR that are more accurate but do not allow simultaneous analysis of several genes. MAPH and MLPA techniques have initiated the change in the management of CNMs, allowing simultaneous analysis of various exons and genes responsible for similar diseases. Moreover, the emergence of commercial kits, providing better reproducibility, ensured the diffusion of MLPA approach. However, commercial MLPA kits do not allow concomitant analysis of large number of genes. The development of CGH array methodology constituted a real breakthrough. In this study, we describe implementation, validation and interests of a custom CGH array that analyses the 344 exons from 26 genes tested in our diagnostic laboratory.

For the array design, we decided to use variable density of probes depending on gene characteristics. For genes with small genomic size, we opted for a HD of probes in exons and introns. For the DMD and the CFTR genes, which are frequently analyzed, we chose a HD of probes in exons and introns to facilitate identification of intronic breakpoints. For the other large genes, we decided to place a lower density of probes in introns to save space on the chip. Intergenic regions were covered by backbone probes to maintain baseline stability between genes. This design appeared to us generally satisfactory in terms of sensitivity and specificity. By taking into account strict quality criteria, as the mad1dr value to validate each experiment, we did not have any false-negative results among the 38 control DNA samples. In a second phase of the study, we tested 345 cases not previously tested and identified 178 exonic CNMs in different genes (162 in DMD, 8 in MECP2, 2 in CDKL5, 3 in CFTR and 3 in the F8 gene). Single-exon CNMs were clearly identified and sensitivity threshold was of 1.4 kb (but no smaller rearrangement was available in this series). In some genes like KAL1, CNMs are difficult to detect by PCR-based techniques because of a homologous gene (KALP on chromosome Y in the case of KAL1). We correctly identified three deletions of the KAL1 gene, and detected one case of neomutation. The fact that oligonucleotide CGH array technique is based on the hybridization of DNA on multiple probes spread all along the target sequence allows to avoid false-negative and false-positive results obtained with the use of PCR techniques and MLPA. Our custom CGH array was efficient to determine the size of the deleted/duplicated fragments. Accuracy of this design was sufficient to allow targeted sequencing of breakpoints of CNMs in the DMD gene, as the average distance between breakpoints indicated by CGH and those determined by sequencing is <300 bp. Large CNMs involving not only the gene of interest, but also neighboring genes, are not rare and identification of the other genes involved can be important for phenotype–genotype correlations. In our custom CGH array, presence of intergenic (backbone) probes allowed determining large rearrangements extending outside of the gene region as illustrated for MECP2, LIS1 and KAL1. In a patient of our series with Kallmann syndrome associated with ocular albinism, CGH array allowed to identify a large deletion encompassing not only the KAL1 gene but also the GPR143 gene, which is known to be associated with ocular albinism phenotypes.34

Custom oligonucleotide CGH array technology also appears particularly efficient to detect and characterize precisely the nature of complex rearrangements that are rare but delicate to identify with current techniques including RT-PCR. In fact, we identified several cases of double duplications or complex rearrangements associating duplication and triplication of several exons in different genes (DMD, CFTR and MECP2), and demonstrated that their characterization is facilitated by simultaneous visualization of the entire rearrangement. For instance, we identified in the DMD gene a particularly complex rearrangement that associates duplications and triplications of several, non-consecutive exons. To our knowledge, and while waiting for contributions from large-scale sequencing, only targeted CGH array approach allows to easily define extent and exons copy-numbers of complex rearrangements that is important for accurate familial studies (carrier determination and prenatal diagnosis) and for phenotype–genotype correlation studies. Somatic mosaicisms are even rarer, but their identification is important for genetic counseling. We tested a women suspected of having a somatic mosaicism of a duplication of two exons in the DMD gene. The clear visualization of the entire duplication in this woman allowed us to confirm that she was a carrier for the mutation and to provide a more appropriate genetic counseling. We also used CGH array for carrier status determination in some families without available index case. This approach was particularly conclusive in our experience for dystrophinopathies, hemophilia A and Kallmann syndrome carriers, but can be applied for all diseases with large rearrangements.

In addition to its efficiency and sensitivity, this custom CGH array is very powerful as it allows simultaneous analysis of a large number of exons (344 exons) corresponding to 26 disease genes. The 12-plex CGH array can detect CNMs, which are different in localization, type and size in a time <5 days for one experiment of 12 patients. If one wants to analyze the 26 genes by MLPA, which is a multistep approach, he would need to use eight different kits, with a working time of 2 days by kit and a cost at least double per sample. Moreover, some of the genes analyzed by our custom CGH array are not available on MLPA kits (in particular the EMD gene and tubulin genes), and in kits such as the XLMR genes, analyses are not exhaustive as probes are present for only some of the exons.

In conclusion, custom oligonucleotide-based CGH array has an undeniable input for diagnosis compared with conventional techniques by improving reliability and accuracy of CNM detection. The possibility of simultaneous analysis of several genes and its scalability make it a valuable tool for a new diagnostic approach of CNMs and should facilitate the molecular diagnosis of heterogeneous groups of diseases such as muscular dystrophies16 or mental retardation. It is the first technology that allows determination of CNM boundaries precisely enough to guide targeted sequencing of breakpoints.35 Possibility of high scale sequencing of breakpoints will bring real progress in understanding molecular mechanisms of rearrangements, searching for genotype–phenotype correlations and to guide certain therapeutic strategies.

We are grateful for the patients and parents for their contribution in the study. We also thank the physicians for referring patients to our laboratory. We thank Sylvie Tuffery-Giraud for her help during the manuscript submission. This work was supported by the Assistance Publique–Hôpitaux de Paris, INSERM, CNRS, Université Paris Descartes and by the NMD-CHIP Consortium, a FP7 HEALTH project of the European Commission (Development of Targeted DNAChips for High-Throughput Diagnosis of Neuromuscular Disorders – Collaborative Project –FP7 Grant Agreement Number: HEALTH-F5-2008-223026).


The authors declare no conflict of interest.

Quemener S,Chen JM,Chuzhanova N,et al. Complete ascertainment of intragenic copy number mutations (CNMs) in the CFTR gene and its implications for CNM formation at other autosomal lociHum MutatYear: 20103142142820052766
Deburgrave N,Daoud F,Llense S,et al. Protein- and mRNA-based phenotype-genotype correlations in DMD/BMD with point mutations and molecular basis for BMD with nonsense and frameshift mutations in the DMD geneHum MutatYear: 20072818319517041906
Tuffery-Giraud S,Beroud C,Leturcq F,et al. Genotype-phenotype analysis in 2,405 patients with a dystrophinopathy using the UMD-DMD database: a model of nationwide knowledgebaseHum MutatYear: 20093093494519367636
Ferec C,Casals T,Chuzhanova N,et al. Gross genomic rearrangements involving deletions in the CFTR gene: characterization of six new events from a large cohort of hitherto unidentified cystic fibrosis chromosomes and meta-analysis of the underlying mechanismsEur J Human GenetYear: 20061456757616493442
Casilli F,Di Rocco ZC,Gad S,et al. Rapid detection of novel BRCA1 rearrangements in high-risk breast-ovarian cancer families using multiplex PCR of short fluorescent fragmentsHum MutatYear: 20022021822612203994
Schouten JP,McElgunn CJ,Waaijer R,Zwijnenburg D,Diepvens F,Pals G. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplificationNucleic Acids ResYear: 200230e5712060695
White S,Kalf M,Liu Q,et al. Comprehensive detection of genomic duplications and deletions in the DMD gene, by use of multiplex amplifiable probe hybridizationAm J Hum GenetYear: 20027136537412111668
del Gaudio D,Yang Y,Boggs BA,et al. Molecular diagnosis of Duchenne/Becker muscular dystrophy: enhanced detection of dystrophin gene rearrangements by oligonucleotide array-comparative genomic hybridizationHum MutatYear: 2008291100110718752307
Audrezet MP,Chen JM,Raguenes O,et al. Genomic rearrangements in the CFTR gene: extensive allelic heterogeneity and diverse mutational mechanismsHum MutatYear: 20042334335715024729
Hegde MR,Chin EL,Mulle JG,Okou DT,Warren ST,Zwick ME. Microarray-based mutation detection in the dystrophin geneHum MutatYear: 2008291091109918663755
Vissers LE,Veltman JA,van Kessel AG,Brunner HG. Identification of disease genes by whole genome CGH arraysHum Mol GenetYear: 200514((Spec No. 2):R215R22316244320
Bovolenta M,Neri M,Fini S,et al. A novel custom high density-comparative genomic hybridization array detects common rearrangements as well as deep intronic mutations in dystrophinopathiesBMC GenomicsYear: 2008957219040728
Saillour Y,Cossee M,Leturcq F,et al. Detection of exonic copy-number changes using a highly efficient oligonucleotide-based comparative genomic hybridization-array methodHum MutatYear: 2008291083109018683213
Wong LJ,Dimmock D,Geraghty MT,et al. Utility of oligonucleotide array-based comparative genomic hybridization for detection of target gene deletionsClin ChemYear: 2008541141114818487280
Staaf J,Torngren T,Rambech E,et al. Detection and precise mapping of germline rearrangements in BRCA1, BRCA2, MSH2, and MLH1 using zoom-in array comparative genomic hybridization (aCGH)Hum MutatYear: 20082955556418330910
Piluso G,Dionisi M,Del Vecchio Blanco F,et al. Motor chip: a comparative genomic hybridization microarray for copy-number mutations in 245 neuromuscular disordersClin ChemYear: 2011571584159621896784
Trabelsi M,Kavian N,Daoud F,et al. Revised spectrum of mutations in sarcoglycanopathiesEur J Human GenetYear: 20081679380318285821
Manilal S,Recan D,Sewry CA,et al. Mutations in Emery-Dreifuss muscular dystrophy and their effects on emerin protein expressionHum Mol GenetYear: 199878558649536090
Vencesla A,Baena M,Garrido RP,et al. F8 gene dosage defects in atypical patients with severe haemophilia AHaemophiliaYear: 20121870871322621702
Van Esch H,Bauters M,Ignatius J,et al. Duplication of the MECP2 region is a frequent cause of severe mental retardation and progressive neurological symptoms in malesAm J Hum GenetYear: 20057744245316080119
Hardwick SA,Reuter K,Williamson SL,et al. Delineation of large deletions of the MECP2 gene in Rett syndrome patients, including a familial case with a male probandEur J Human GenetYear: 2007151218122917712354
Nemos C,Lambert L,Giuliano F,et al. Mutational spectrum of CDKL5 in early-onset encephalopathies: a study of a large collection of French patients and review of the literatureClin GenetYear: 20097635737119793311
Papa FT,Mencarelli MA,Caselli R,et al. A 3 Mb deletion in 14q12 causes severe mental retardation, mild facial dysmorphisms and Rett-like featuresAm J Med Genet AYear: 2008146A1994199818627055
Ariani F,Hayek G,Rondinella D,et al. FOXG1 is responsible for the congenital variant of Rett syndromeAm J Hum GenetYear: 200883899318571142
Borg I,Freude K,Kubart S,et al. Disruption of Netrin G1 by a balanced chromosome translocation in a girl with Rett syndromeEur J Human GenetYear: 20051392192715870826
Shoichet SA,Duprez L,Hagens O,et al. Truncation of the CNS-expressed JNK3 in a patient with a severe developmental epileptic encephalopathyHum GenetYear: 200611855956716249883
Hammond LS,Macias MM,Tarleton JC,Shashidhar Pai G. Fragile X syndrome and deletions in FMR1: new case and review of the literatureAm J Med GenetYear: 1997724304349375726
Sahoo T,Theisen A,Marble M,et al. Microdeletion of Xq28 involving the AFF2 (FMR2) gene in two unrelated males with developmental delayAm J Med Genet AYear: 2011155A3110311522065534
Kato M,Das S,Petras K,et al. Mutations of ARX are associated with striking pleiotropy and consistent genotype-phenotype correlationHum MutatYear: 20042314715914722918
Haverfield EV,Whited AJ,Petras KS,Dobyns WB,Das S. Intragenic deletions and duplications of the LIS1 and DCX genes: a major disease-causing mechanism in lissencephaly and subcortical band heterotopiaEur J Human GenetYear: 20091791191819050731
Lo Nigro C,Chong CS,Smith AC,Dobyns WB,Carrozzo R,Ledbetter DH. Point mutations and an intragenic deletion in LIS1, the lissencephaly causative gene in isolated lissencephaly sequence and Miller-Dieker syndromeHum Mol GenetYear: 199761571649063735
Dode C,Hardelin JP. Kallmann syndromeEur J Human GenetYear: 20091713914618985070
Hardelin JP,Levilliers J,Young J,et al. Xp22.3 deletions in isolated familial Kallmann's syndromeJ Clin Endocrinol MetabYear: 1993768278318473391
Bassi MT,Schiaffino MV,Renieri A,et al. Cloning of the gene for ocular albinism type 1 from the distal short arm of the X chromosomeNat GenetYear: 19951013197647783
Ishmukhametova A,Van Kien PK,Mechin D,et al. Comprehensive oligonucleotide array-comparative genomic hybridization analysis: new insights into the molecular pathology of the DMD geneEur J Human GenetYear: 2012201096110022510846

Article Categories:
  • Article

Keywords: CGH array, oligonucleotide probes, copy-number mutations, CNMs, complex rearrangements.

Previous Document:  A Delphi study to determine the European core curriculum for Master programmes in genetic counsellin...
Next Document:  Exploring resources for intrafamilial communication of cancer genetic risk: we still need to talk.